Our Story

 

Hydrogen inhalation is one of the most effective ways to deliver high doses of molecular hydrogen—fast, safe, and ideal for those who can’t tolerate large fluid intake, say from tablets. Inhale H₂ was born from a shared mission to make hydrogen inhalation safe, effective, and accessible. In 2018, Tyler W. LeBaron, MSc, PhD, and Alex Tarnava (inventor of the open-cup H₂-producing tablets) were discussing the growing body of research on hydrogen water and hydrogen gas inhalation.

This conversation led to concerns about the inhalation devices available on the market. Most units delivered hydrogen at flow rates either so low they were unlikely to be therapeutic, or high enough to be therapeutic, but also flammable. As a result, many clinics, hospitals, and research institutions were unable to safely explore hydrogen inhalation therapy

Dr. LeBaron stated that even in his own PhD research—and in other major studies— researchers had to use premixed gas tanks to deliver precise therapeutic concentrations of hydrogen while remaining safely below the flammability threshold.

The more they spoke, the more they realized their goals aligned: to create a device that safely delivered non-flammable hydrogen gas while ensuring every inhaled breath—regardless of body size or breathing pattern—achieved a clinically relevant and precise concentration.

Alex committed to building a machine that would bring this shared vision to life, and he asked Dr. LeBaron to consult on the project. The journey that followed was long and challenging. Despite years of collaboration with top-tier manufacturing partners, none of them were able to fully grasp the innovation behind the design, preferring to push their existing models. Others resisted a disruptive concept that challenged the status quo.

Eventually, the team shifted its engineering operations, and partnered with experienced U.S.-based design firms to reduce reliance on foreign manufacturers. After multiple failed prototypes—with each iteration bringing greater clarity—a viable alpha unit was finally achieved, followed by a successful beta model.

The beta units were distributed to 50 select partners and unveiled at the Health Optimization Summit in Austin, TX. The response was overwhelmingly positive. Six weeks of field testing confirmed the machine consistently delivered a safe, precise, and therapeutically-effective hydrogen concentration. Feedback from beta users led to further refinement, improving both the user experience and overall usability.

Now, after seven years of development—and for the first time in over 16 years—Dr. LeBaron has officially endorsed a hydrogen product, and has chosen to serve as the Chief Scientific Officer for InhaleH₂. While he remains committed to his academic research, his leadership at MHI, and his independent advisory roles, this marks a milestone with Dr. LeBaron’s first public endorsement of a specific hydrogen technology.

Inhale H2 is Hydrogen Therapy, Refined for Results
Designed by industry experts for accurate dosing, medical-grade safety, and reliable therapeutic impact—breath after breath.